Medical
-
According to the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Ferring Pharmaceuticals has recalled multiple batches of Desmospray 0.1 mg/ml desmopressin, Aspire branded desmopressin 0.1 mg/ml, and Octim desmopressin 1.5 mg/ml nasal sprays “due… Read more . . .
-
Altimmune has announced that a study of its AdCOVID intranasal vaccine candidate induced a strong immune response in a mouse model. The results support advancing AdCOVID into a Phase 1 development, the company said, and… Read more . . .
-
Vienna-based biotech incubator CEBINA (Central European Biotech Incubator and Accelerator) said that in vitro testing has shown that azelastine has anti-SARS-CoV-2 activity, and the company is discussing possible development and production of an azelastine nasal spray for the… Read more . . .
-
Dutch inhaled drug developer PureIMS said that it has initiated a Phase 1 clinical trial of its Amikacin Cyclops DPI, which it is developing for the treatment of drug susceptible tuberculosis. The single ascending dose… Read more . . .
-
Orexo has announced that a Phase 1 bioavailability study of three formulations of its OX125 intranasal nalmefene compared to intramuscular nalmefene injection showed that all three were well tolerated and well absorbed. Orexo is developing… Read more . . .
-
Meissa Vaccines has provided updates on two intranasal live attenuated vaccines (LAVs) based on its “codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.” The company said that… Read more . . .
-
TFF Pharmaceuticals has announced topline safety results from a Phase 1 trial of its inhaled dry powder voriconazole, which is in development for the treatment of invasive pulmonary aspergillosis. The study demonstrated that doses as… Read more . . .
-
AstraZeneca said that complete results from the Phase 3 ETHOS trial of its Breztri Aerosphere (PT010) budesonide/glycopyrronium/formoterol fumarate MDI demonstrated that the triple combination reduced moderate or severe COPD exacerbations by 24% compared to glycopyrronium/formoterol… Read more . . .
-
Gilead Sciences Chairman and CEO Daniel O’Day has announced that the company has received FDA approval for a Phase 1 trial of inhaled remdesivir and will initiate the study within a week. Trials of the… Read more . . .
-
Vaccine developer Intravacc has published data from a preclinical study of an intranasal whooping cough vaccine demonstrating strong immune responses in mice. The intranasal vaccine also prevented colonization of the lung, trachea, and nose by… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland